Yale researchers have identified that the acute inflammatory response to biomaterials can be limited by inhibition of inflammasome-related pathways.
OCR3105/5254 pertains to the creation of a simple tool kit for the efficient site specific, phosphorylation signal-independent, introduction of phosphoserine into proteins in vitro and in vivo using a novel vector compatible with complementary bacterial strains and mammalian tissue culture.
Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases. Semaphorin 7A inhibition is also effective as a therapeutic treatment for fibrotic disease.
Yale researchers created an inactivated version of the thyphoid toxin, which can serve as the basis for the development of novel second-generation vaccines to treat typhoid fever.
OCR 5339 is a novel serum-based biomarker assay that determines disease severity and provides a prediction of the progression of scleroderma.
GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.